BioTelemetry, Inc. Reports Second Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioTelemetry, Inc. Reports Second Quarter 2014 Financial Results

MALVERN, Pa., July 31, 2014 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (Nasdaq: BEAT ), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2014.

Company Highlights

  • Revenue increased 33% to $42.7 million, the highest quarterly revenue in the Company's history
  • Serviced over 135,000 patients in the quarter, doubling our prior year volume
  • Generated positive adjusted EBITDA of $5.1 million
  • Completed the acquisition of the cardiac patient services business of Biomedical Systems, Corp. ("BMS")
  • Completed the acquisition of the assets of Radcore Lab, LLC, an imaging core lab
  • Reached an agreement in principle for a potential settlement with the Department of Justice

President and CEO Commentary

Joseph Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: "We are pleased to report our successful second quarter results in which we recognized $42.7 million of revenue and we serviced over 135,000 patients, which is more than twice the volume of the second quarter of 2013 and the highest quarterly volume and revenue in the history of the Company. These results were attributable to strong organic volume growth of 16% and our acquisitions of BMS and Mednet, which provide us broader access to established physician relationships. We also continue to make progress with our product development, highlighted by the expected launch of our new low-cost Holter device in the fourth quarter of this year and our cutting edge next generation MCOT TM device in 2015. Our Research Services business continues to gain momentum with the recent addition of two of the largest studies in the Company's history and significant growth in the Company's backlog. The acquisition of Radcore Lab, an imaging core lab, allows us to offer our clinical research customers access to an expanded range of services.

"We also reached an agreement in principle for a settlement of $6.4 million with the U.S. Department of Justice in connection with the Civil Investigative Demand that we received in 2011, subject to negotiation of a final agreement. We are looking forward to having this matter resolved.

"Our positive second quarter was the direct result of our ability to deliver on our three core strategic objectives: to solidify our leadership position in cardiac monitoring, establish a leading research services business and leverage our existing infrastructure in new markets. As a result, we were able to deliver solid revenue growth and an improved operating margin, while continuing to foster new growth opportunities. We are excited about our future prospects and look forward to delivering strong results."

Second Quarter Financial Results

Revenue for the second quarter 2014 was $42.7 million, an increase of 32.8% compared to $32.1 million in the second quarter 2013. Total revenue increased $10.5 million due to an increase in patient services revenue of $9.3 million and an increase in product sales of $1.3 million. Approximately $8.4 million of the total increase was related to acquisitions. The remaining increase was due to organic volume growth which was partially offset by the previously announced price reduction from Medicare, and related contracts. For the three months ended June 30, 2014, patient revenue was comprised of 40% Medicare and 60% commercial.

Gross profit for the second quarter 2014 increased to $23.6 million, or 55.4% of revenue, compared to $19.5 million, or 60.7% of revenue, in the second quarter of 2013. Gross profit for the second quarter 2014 on an adjusted basis was $23.9 million, or 56.1% of revenue, excluding $0.3 million related to restructuring and other charges. This compares to gross profit for the second quarter 2013 on an adjusted basis of $19.8 million, or 61.5% of revenue, excluding $0.3 million related to restructuring and other charges. The decrease in the gross profit percentage was related to the acquisitions, including the impact of a lower margin patient mix of 350 basis points and the impact of integration related activities of 130 basis points that will not reoccur. The benefit from the organic patient growth was substantially offset by the reduction in reimbursement rates.

On a GAAP basis, operating expenses for the second quarter 2014 were $24.0 million, an increase of 10.5% compared to $21.7 million in the second quarter 2013. On an adjusted basis, operating expenses for the second quarter were $23.0 million, a 20.3% increase compared to $19.1 million for the prior year quarter. These adjusted operating expenses exclude $1.0 million in the second quarter 2014 primarily due to integration activities, patent litigation and legal fees related to the Civil Investigative Demand and $2.5 million in the second quarter 2013 primarily related to patent litigation and integration activities. The increase in adjusted operating expense was driven by the addition of Mednet and BMS. Adjusted operating expense in the base business was essentially flat.

On a GAAP basis, interest and other loss, net for the second quarter 2014 was $3.6 million, compared to $0.1 million in the second quarter of 2013. During the first quarter 2014, the Company began negotiations for a potential settlement with the Department of Justice regarding the outstanding Civil Investigative Demand issued in August 2011. As a result, the Company recorded an estimated reserve of $3.3 million as a non-operating charge in the second quarter 2014. This is in addition to the $3.1 million reserve recorded for this matter in the first quarter 2014. Excluding this reserve, interest and other loss, net for the second quarter was $0.3 million, a slight increase compared to the prior year due to the addition of debt and capital leases.

On a GAAP basis, net loss for the second quarter 2014 was $4.0 million, or a loss of $0.15 per diluted share, compared to a net loss of $2.3 million, or a loss of $0.09 per diluted share, for the second quarter 2013. Excluding expenses related to restructuring and other charges, including the $3.3 million reserve for the potential settlement with the Department of Justice, adjusted net income for the second quarter 2014 was $0.6 million, or income of $0.02 per diluted share. This compares to adjusted net income of $0.6 million, or income of $0.02 per diluted share, for the second quarter 2013, which excludes the impact of restructuring and other charges.

Liquidity

As of June 30, 2014, total cash was $13.5 million, a decrease of $8.6 million compared to December 31, 2013. The significant uses of cash during the second quarter 2014 included $3.8 million for capital expenditures, primarily for medical devices and the development of a new Patient Services operating system. Consolidated days sales outstanding were 50 days, in-line with year-end 2013.

Conference Call     

BioTelemetry, Inc. will host an earnings conference call on Thursday, July 31, 2014, at 5:00 PM Eastern Time. The call will be simultaneously webcast on the investor information page of our website, www.biotelinc.com . The call will be archived on our website for two weeks.

About BioTelemetry

BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.biotelinc.com .

Cautionary Statement Regarding Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "expect," "anticipate," "estimate," "intend," "plan," "believe," "promises" and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, our ability to successfully integrate the Mednet, Biomedical Systems and Radcore businesses into our business and the effect such acquisitions will have on our results of operation, our ability to successfully negotiate a settlement to the Department of Justice investigation prior to any judicial action, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

 
     
  Three Months Ended
Consolidated Statements of Operations (unaudited)
(In Thousands, Except Per Share Amounts)    
     
  June 30,
2014
June 30,
2013
     
Revenue $42,650 $32,104
Cost of revenue  19,037 12,608
Gross profit 23,613 19,496
Gross profit % 55.4% 60.7%
     
Operating expenses:    
General and administrative expense 11,139 9,077
Sales and marketing expense 7,172 6,267
Bad debt expense 2,745 1,967
Research and development expense 1,958 1,882
Integration, restructuring and other charges 1,000 2,541
Total operating expenses 24,014 21,734
     
Loss from operations (401) (2,238)
Interest and other (loss), net (3,587) (61)
     
Loss before income taxes  (3,988) (2,299)
Benefit from income taxes --   --
Net loss  $ (3,988)  $ (2,299)
     
     
Loss per Share:    
 Basic  $ (0.15)  $ (0.09)
 Diluted  $ (0.15)  $ (0.09)
     
Weighted Average Shares Outstanding:    
 Basic 26,434 25,537
 Diluted 26,434 25,537
 
     
  Six Months Ended
Consolidated Statements of Operations (unaudited)
(In Thousands, Except Per Share Amounts)    
     
  June 30,
2014
June 30,
2013
     
Revenue $79,812 $64,522
Cost of revenue  34,555 25,481
Gross profit 45,257 39,041
Gross profit % 56.7% 60.5%
     
Operating expenses:    
General and administrative expense 21,911 18,605
Sales and marketing expense 14,612 13,029
Bad debt expense 5,104 4,434
Research and development expense 3,747 3,502
Integration, restructuring and other charges 3,980 3,743
Total operating expenses 49,354 43,313
     
Loss from operations (4,097) (4,272)
Interest and other (loss), net (6,858) (114)
     
Loss before income taxes  (10,955) (4,386)
Benefit from income taxes 2,845  -- 
Net loss  $ (8,110)  $ (4,386)
     
     
Loss per Share:    
 Basic  $ (0.31)  $ (0.17)
 Diluted  $ (0.31)  $ (0.17)
     
Weighted Average Shares Outstanding:    
 Basic 26,272 25,370
 Diluted 26,272 25,370
 
Summary Financial Data    
(In Thousands)    
  June 30,
2014
December 31,
2013
  (unaudited) (unaudited)
     
Cash and investments $ 13,546 $ 22,151
Patient accounts receivable, net 15,702 11,437
Other accounts receivable, net 7,877 5,680
Days sales outstanding 50 47
Working capital 5,941 25,215
Total assets 118,409 87,546
Total debt 17,636 --
Total shareholders' equity 62,700 66,829
     
Reconciliation of Non-GAAP Financial Measures
(In Thousands, Except Per Share Amounts)
     
In accordance with Regulation G of the Securities and Exchange Commission, the table set forth below reconciles certain financial measures used in this press release that were not calculated in accordance with generally accepted accounting principles, or GAAP, with the most directly comparable financial measure calculated in accordance with GAAP.
     
  Three Months Ended
  (unaudited)
  June 30,
2014
June 30,
2013
Operating loss – GAAP  $ (401)  $ (2,238)
Nonrecurring charges (a) 1,320 2,859
Adjusted operating income (loss)  $ 919  $ 621
     
Net loss – GAAP   $ (3,988)  $ (2,299)
Nonrecurring charges (b) 4,626 2,859
Adjusted net income (loss)  $ 638  $ 560
     
Loss per diluted share – GAAP  $ (0.15)  $ (0.09)
Nonrecurring charges per share (b) 0.17 0.11
Adjusted earnings (loss) per diluted share   $ 0.02  $ 0.02
     
(a)  In the second quarter of 2014, the Company incurred $1.0 million of integration, restructuring and other charges primarily related to the integration of the Company's recent acquisitions and legal fees for patent litigation and the Civil Investigative Demand. The Company also incurred $0.3 million of other expense for duplicative labor due to the planned relocation of certain business functions. In the second quarter of 2013, the Company incurred $2.5 million related to integration, restructuring and other charges primarily related to patent litigation, $0.3 million of other expense for duplicative labor due to the relocation of certain business functions and $0.1 million for the forfeiture and acceleration of certain options. 
(b) In addition to the $1.3 million of nonrecurring charges incurred in the second quarter 2014, the Company recorded a non-operating charge of $3.3 million for the potential settlement with the Department of Justice
     
   Three Months Ended
  (unaudited)
  June 30,
2014
June 30,
2013
     
Cash provided (used) by operating activities  $ 5,929  $ 2,505
Capital expenditures (3,751) (1,586)
Free cash flow  $ 2,178  $ 919
     
     
   Three Months Ended
  (unaudited)
  June 30,
2014
June 30,
2013
     
Operating loss – GAAP  $ (401)  $ (2,238)
Nonrecurring charges 1,320 2,859
Depreciation and amortization expense 3,242 2,736
Stock compensation expense 965 957
Adjusted EBITDA   $ 5,126  $ 4,314
     
Reconciliation of Non-GAAP Financial Measures
(In Thousands, Except Per Share Amounts)
     
In accordance with Regulation G of the Securities and Exchange Commission, the table set forth below reconciles certain financial measures used in this press release that were not calculated in accordance with generally accepted accounting principles, or GAAP, with the most directly comparable financial measure calculated in accordance with GAAP.
     
  Six Months Ended
  (unaudited)
  June 30,
2014
June 30,
2013
Operating loss – GAAP  $ (4,097)  $ (4,272)
Nonrecurring charges (a) 4,300 4,235
Adjusted operating income (loss)  $ 203  $ (37)
     
Net loss – GAAP   $ (8,110)  $ (4,386)
Nonrecurring charges (b) 7,830 4,235
Adjusted net loss  $ (280)  $ (151)
     
Loss per diluted share – GAAP  $ (0.31)  $ (0.17)
Nonrecurring charges per share (b) 0.30 0.16
Adjusted loss per diluted share  $ (0.01)  $ (0.01)
     
(a)  In the first six months of 2014, the Company incurred $4.0 million of integration, restructuring and other charges primarily due to legal fees related to patent litigation and the Civil Investigative Demand, as well as acquisition and integration related charges for Mednet and BMS. The Company also incurred $0.3 million of other expense for duplicative labor due to the planned relocation of certain business functions. In the first six months of 2013, the Company incurred $3.7 million related to integration, restructuring and other charges primarily due to patent litigation, integration costs and costs associated with the creation of the Company's holding company structure. The Company also incurred $0.3 million of other expense for duplicative labor due to the relocation of certain business functions and $0.1 million for the forfeiture and acceleration of certain options. 
(b)  In addition to the $4.3 million of nonrecurring charges incurred in the second quarter 2014, the Company recorded a non-operating charge of $3.3 million for the potential settlement with the Department of Justice. 
     
   Six Months Ended
  (unaudited)
  June 30,
2014
June 30,
2013
     
Cash provided (used) by operating activities  $ 3,869  $ 4,162
Capital expenditures (7,610) (3,425)
Free cash flow  $ (3,741)  $ 737
     
     
   Six Months Ended
  (unaudited)
  June 30,
2014
June 30,
2013
     
Operating loss – GAAP  $ (4,097)  $ (4,272)
Nonrecurring charges 4,300 4,235
Depreciation and amortization expense 5,995 5,744
Stock compensation expense 1,968 1,574
Adjusted EBITDA   $ 8,166  $ 7,281

BioTelemetry, Inc. Heather C. Getz Investor Relations 800-908-7103

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading